The company operates boutique cardiac hospitals under the Maple Hospitals brand, providing non-invasive and interventional cardiology services including diagnostics, stenting, and pacemaker implantations.
The company lacks a durable moat as evidenced by low ROCE (9.5%) and ROE (9.3%) which barely cover the cost of capital. While they operate in a specialized niche, the negative cash conversion and high reliance on promoter-led related party transactions suggest a lack of structural competitive advantage or scale.
Capital has been primarily directed toward acquiring assets from the promoter's existing private practice and funding significant rent deposits to the promoter. The negative cash conversion and declining EPS despite revenue growth indicate inefficient deployment of capital.
The business collapsed as the disconnect between accounting revenue and actual cash flow became unsustainable. While the top line grew, the capital was systematically drained through related-party transactions, including inflated rent deposits and equipment purchases from the promoter's private interests. The negative cash conversion cycle eventually starved the operations of liquidity, and the lack of a genuine competitive advantage meant the hospital could not raise prices to offset the rising costs of its inefficient capital structure, leading to a permanent impairment of shareholder value.
RichFakir rates Broach Lifecare Hospital Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Broach Lifecare Hospital Ltd is trading about 100% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Broach Lifecare Hospital Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Broach Lifecare Hospital Ltd's fair value is about ₹6 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →